Carsten Denkert
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
TransLUMINAL-B
Open Date: 2015-07-01
Close Date: 2018-06-01
Grant: Close
Transcan UGI-1
Open Date: 2014-01-01
Close Date: 2016-01-01
Grant: Close
RESPONSIFY
Open Date: 2012-01-01
Close Date: 2015-01-01
Grant: Close
ARROWS
Open Date: 2009-01-01
Close Date: 2012-01-01
Grant: Close
METAcancer FP7
Open Date: 2008-01-01
Close Date: 2011-01-01
Articles (22)
IDFS by HER2 IHC score at definitive surgery (derived from samples used for eligibility and exploratory purposes). IDFS, invasive disease-free survival; IHC, immunohistochemistry; T-DM1, trastuzumab emtansine.
Year:
2025
HER2, PD-L1, and Five-Gene Signature Quartile Analysis. IDFS by HER2 gene expression quartile (A) in the trastuzumab arm; and (B) in the T-DM1 arm; (C) treatment effect on IDFS by HER2 gene expression quartile; (D) effect of HER2 gene expression quartile on IDFS; IDFS by PD-L1 gene expression quartile (E) in the trastuzumab arm; and (F) in the T-DM1 arm; (G) treatment effect on IDFS by PD-L1 gene expression quartile; (H) effect of PD-L1 gene expression quartile on IDFS; IDFS by five-gene signature (i.e., PD-L1/granzymeB/CD8/IFNγ/CXCL9) gene expression quartile (I) in the trastuzumab arm; and (J) in the T-DM1 arm; (K) treatment effect on IDFS by five-gene signature gene expression quartile; (L) effect of five-gene signature gene expression quartile expression on IDFS. Each expression quartile (quartile 2, quartile 3, and quartile 4) is compared to the lowest quartile (quartile 1). The analyses are unstratified and adjusted using a Cox regression model that includes percent tumor in marked area, clinical stage at presentation, hormone receptor status, type of preoperative HER2-directed therapy, and pathologic nodal status. HER2, human epidermal growth factor receptor 2; IDFS, invasive disease-free survival; IFNγ, interferon gamma; Q, quartile; T-DM1, trastuzumab emtansine.
Year:
2025
Comparison of HER2 expression intensity in paired pre-NAT (i.e., before surgery) and post-NAT surgical samples. HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NAT, neoadjuvant therapy.
Year:
2025
Comparison of IDFS outcomes in the ITT population compared to the (A) RNA-evaluable population (REP) (including pre- and post-NAT surgical samples) and in patients with (B) pre-NAT REP samples (left) or post-NAT surgical REP samples (right). HER2, human epidermal growth factor receptor 2; IDFS, invasive disease-free survival; IHC, immunohistochemistry; ITT, intent-to-treat; NAT, neoadjuvant therapy; T-DM1, trastuzumab emtansine.
Year:
2025
Comparison of baseline patient and disease characteristics assessed at eligibility in the ITT population versus in those with mRNA data derived from pre-NAT or post-NAT surgical samples (RNA-evaluable population). Note: the pre-NAT and post-NAT samples are not paired.
Year:
2025
Comparison of pre-NAT and post-NAT surgical RNA-evaluable samples. (A) ERBB2 (i.e., HER2), CD274 (i.e., PD-L1), checkpoint inhibitor signature (i.e., PD-L1/PD-L2/IDO), CD8A (i.e., CD8), TEFF signature CD8/granzymeA/granzymeB/perforin/IFNγ), three-gene signature (i.e., PD-L1/IFNγ/CXCL9), five-gene signature (i.e., PD-L1/granzymeB/CD8/IFNγ/CXCL9), Th1 cytokine signature (i.e., CXCL9/CXCL10/CXCL11), and B cell gene expression. (B) Frequency of AIMS PAM50 subtypes overall and by hormone receptor status. (C) Frequency of AIMS PAM50 subtypes by level of HER2 protein expression assessed by IHC in pre- and post-NAT samples. (D) Frequency of AIMS PAM50 subtypes by level of HER2 gene expression in pre- and post-NAT samples. (E) Hallmark gene sets enriched for genes upregulated in post-NAT surgical versus pre-NAT samples (adjusted P
Year:
2025
Prognostic value for IDFS by treatment arm of biomarker gene expression levels (>median vs. ≤median and continuous) in post-NAT surgical RNA-evaluable tissue samples. Analysis is adjusted for tumor content. One sample could not be included because there was insufficient information on tumor content.
Year:
2025
Comparison of HER2 expression heterogeneity in paired pre-NAT (i.e., before surgery) and post-NAT surgical samples. Patients were categorized according to whether HER2 staining was focal (
Year:
2025
Figure S8 depicts GSEA for Millstein sub-signatures in the Charité cohort. Gene sets were incrementally increased by one gene at thetime (see color code). X-axis shows the NES and only the full 101-gene signature was significantly enriched.
Year:
2025
Purpose: The late-stage diagnosis and the aggressiveness of high-grade serous tubo-ovarian carcinoma (HGSC) often result in poor survival outcomes, yet some patients exhibit an exceptionally long survival rate. This study aimed to identify molecular profiles associated with long-/short-term survival in HGSC, with the goal of better understanding protective factors and developing new treatments. Experimental Design: To discover molecular drivers causing the aggressiveness of HGSC, tumor samples from 12 long-term HGSC survivors (>7 years overall survival) and 12 short-term survivors ( Results: Besides known molecular cancer drivers and indicators of poor prognosis, we identified specific transcriptional changes between short- and long-term survivors of HGSC, which indicate that immune processes play a fundamental role in long-term survivors. Our computational analysis reveals an important role for the ensemble of IFN-γ signaling and the RFX transcription factors, as well as the immune cell composition of the tumor microenvironment. Conclusions: Specific immunologic requirements involving IFN-γ signaling and affected pathways seem to be relevant for long-term survival in the generally considered nonimmunogenic HGSC, necessitating further research to improve diagnostic strategies and targeted therapies.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (20)
alfonso valencia
Research Professor
Instituciò Catalana de Recerca i Estudis Avancats
Eric Hahnen
-
Ioana Braicu
Head of clinical and translational research
Charité - Universitätsmedizin Berlin
Peter Sinn
Head, Division of Gynaecopathology
University Hospital
Charles Edward Geyer Jr
Professor of Medicine in Division of Hematology/Medical Oncology
University of Pittsburgh
Christine Solbach
Goethe University Frankfurt
Judith Balmaña
Head
Hospital Universitari Vall d'Hebron
Jalid Sehouli
Charité - Universitätsmedizin Berlin
Mark Basik
McGill University
Terence Williams
City Of Hope National Medical Center
Judith Lea Lindner
-
Marcus Schmidt
Professor and Head of Molecular Oncology
University Medical Center
Tanja Fehm
Professor
University Hospital Düsseldorf
Thomas Karn
Goethe University Frankfurt
Peter Fasching
-
Guillermo Villacampa Javierre
Biostatistician
Vall d´Hebron Institute of Oncology
Changxian Shen
City of Hope
Peter Lucas
Professor and Vice Chair of Research
Mayo Clinic
Violeta Serra
Group Leader
Vall d'Hebron Institute of Oncology
Paul Jank
Head of Translational Research Laboratory
-
Make your next move.
Prepare your application
Review drafts before you send them.